top of page

Intelligent biosensors that power the future of healthcare

Predict changes. Intervene earlier. Prevent progression.

PercuSense’s continuous multi-analyte sensor system combines monitoring of multiple biosensors with knowledge of how diseases and illness progress to intelligently and proactively recommend treatment.

HOW IT WORKS
AdobeStock_341678401.jpeg

Metabolic Monitoring

Continuous monitoring of lactate and glucose on a single sensor to optimize health and fitness for elite athletes, weekend warriors, and anyone trying to improve their overall health. 

ABOUT US

Why PercuSense?

High Performance, Low-Cost

Calibration-free performance that CGM users are accustomed to, in a more affordable package

Measure Multiple Parameters in a Single Sensor

Glucose, lactate, oxygen, ketones, and more. A combination of measurements tailored to each disease state

PS_icons-03.png
Added Features without
Added Size

The information doubles, but the size doesn't.

Multi-parameter monitoring in a small area

PS_icons-02.png
Unique Innovation Protected with Patents

Robust intellectual property with multiple granted worldwide patents protecting novel ideas

Idea_edited_edited.png

Latest News

PercuSense Will Present at the 2024 ATTD Conference in Florence

February 2, 2024

PercuSense will exhibit and present at the 17th International Conference on Advanced Technologies and Treatments for Diabetes in Florence, Italy and online from March 6-9, 2024. Additionally, PercuSense’s clinical partners at the University of Melbourne will present first-in-human results from PercuSense’s novel CGLM (glucose + lactate).

CONTINUE READING

PercuSense Begins Next Phase in Detecting Indicators of Chemical Exposure

January 5, 2024

PercuSense has begun the fourth phase of collaboration with the Defense Threat Reduction Agency (DTRA) and Defense Innovation Unit (DIU) focused on miniaturization of the biosensor platform to provide for early detection and warning of potential exposure to chemical warfare agents.

CONTINUE READING

First-in-Human Feasibility Testing on Novel Continuous Multi-Analyte Sensor Platform

August 11, 2023

PercuSense has completed groundbreaking first-in-human feasibility testing on its continuous multi-analyte biosensor platform. The study was completed in collaboration with partners at the Diabetes Research Group at the University of Melbourne in Australia, The Helmsley Charitable Trust, and the US Department of Defense. 

CONTINUE READING
NEWS

We're Hiring!

Contact us to learn about current job openings.

TheTeam

The Team

The PercuSense team consists of extremely passionate and capable professionals with over 130 years

of medical technology productization experience in medical devices and continuous monitoring.

CONTACT

Get in Touch

If you would like to inquire about a partnership opportunity or open positions or learn more about PercuSense and our technology, please submit the form below or contact us at connect@percusense.com.

Tel: 661-425-7015

28159 Avenue Stanford | Suite 190 | Valencia, CA 91355

Thanks for submitting!

bottom of page